The development of effective and rational combination immunotherapy capable of yielding improved clinical efficacy beyond existing PD-1/PD-L1 inhibitor therapy hinges upon understanding these immunologic states, the mechanisms that underpin them, and the appropriate targets that can unleash a potent anti-tumor immune response in these specific immunologic contexts. Here, CD274 is linked to neoplasm.